Journal: Neurology® Neuroimmunology & Neuroinflammation

Article Title: Outcome Predictors in Progressive Multifocal Leukoencephalopathy Associated With Multiple Sclerosis Treatments

doi: 10.1212/NXI.0000000000200558

Figure Lengend Snippet: Forest plots representing the effect of predefined predictors on disability, assessed using the mRS at 12 months following disease onset, shown for univariate analysis (A) and multivariable ordinal regression (B). *Within the first 12 months after PML diagnosis. DMF = dimethyl fumarate; DMT = disease-modifying treatments; EDSS = Expanded Disability Status Scale; IRIS = immune reconstitution inflammatory syndrome; JCV = JC virus; mRS = modified Rankin Scale; MS = multiple sclerosis; NTZ = natalizumab; PML = progressive multifocal leukoencephalopathy; RRMS = relapsing-remitting MS; S1P-RM = sphingosine-1-phosphate receptor modulators; SPMS = secondary progressive MS.

Article Snippet: As the primary cause of iatrogenic PML in multiple sclerosis (MS), natalizumab ([NTZ]–Tysabri, Biogen, Cambridge, MA) has been extensively studied over the past years.

Techniques: Biomarker Discovery, Virus, Modification

Journal: Neurology® Neuroimmunology & Neuroinflammation

Article Title: Outcome Predictors in Progressive Multifocal Leukoencephalopathy Associated With Multiple Sclerosis Treatments

doi: 10.1212/NXI.0000000000200558

Figure Lengend Snippet: Forest plots representing the effect of predefined predictors on (A) the risk of developing PML-IRIS and (B) the occurrence of recurring MS activity, based on multivariable binomial regression analysis. DMF = dimethyl fumarate; IRIS = immune reconstitution inflammatory syndrome; MS = multiple sclerosis; NTZ = natalizumab; S1P-RM = sphingosine-1-phosphate receptor modulators.

Article Snippet: As the primary cause of iatrogenic PML in multiple sclerosis (MS), natalizumab ([NTZ]–Tysabri, Biogen, Cambridge, MA) has been extensively studied over the past years.

Techniques: Activity Assay

Journal: Neurology and Therapy

Article Title: Time and Motion Study to Quantify Time for Tysabri (Natalizumab) Intravenous Versus Subcutaneous to Treat Relapsing-Remitting Multiple Sclerosis in France, Spain, and the United Kingdom

doi: 10.1007/s40120-026-00888-1

Figure Lengend Snippet: Patient pathway during the clinic visit and HCP pathway showing generic workflow for natalizumab IV and SC preparation and administration processes. HCP healthcare professional, IV intravenous, SC subcutaneous

Article Snippet: Tysabri (natalizumab), developed by Biogen, is a recombinant humanized IgG4 monoclonal antibody for the treatment of adults with highly active RRMS.

Techniques:

Journal: Neurology and Therapy

Article Title: Time and Motion Study to Quantify Time for Tysabri (Natalizumab) Intravenous Versus Subcutaneous to Treat Relapsing-Remitting Multiple Sclerosis in France, Spain, and the United Kingdom

doi: 10.1007/s40120-026-00888-1

Figure Lengend Snippet: HCP satisfaction with natalizumab preparation. HCP healthcare professional, IV intravenous, SC subcutaneous. 1 = not at all satisfied; 10 = very satisfied

Article Snippet: Tysabri (natalizumab), developed by Biogen, is a recombinant humanized IgG4 monoclonal antibody for the treatment of adults with highly active RRMS.

Techniques:

Journal: Neurology and Therapy

Article Title: Time and Motion Study to Quantify Time for Tysabri (Natalizumab) Intravenous Versus Subcutaneous to Treat Relapsing-Remitting Multiple Sclerosis in France, Spain, and the United Kingdom

doi: 10.1007/s40120-026-00888-1

Figure Lengend Snippet: HCP satisfaction with natalizumab administration. HCP healthcare professional, IV intravenous, SC subcutaneous. 1 = not at all satisfied; 10 = very satisfied

Article Snippet: Tysabri (natalizumab), developed by Biogen, is a recombinant humanized IgG4 monoclonal antibody for the treatment of adults with highly active RRMS.

Techniques:

Journal: Neurology and Therapy

Article Title: Time and Motion Study to Quantify Time for Tysabri (Natalizumab) Intravenous Versus Subcutaneous to Treat Relapsing-Remitting Multiple Sclerosis in France, Spain, and the United Kingdom

doi: 10.1007/s40120-026-00888-1

Figure Lengend Snippet: Mean importance of reasons for preference of natalizumab SC related to preparation. SC subcutaneous. 1 = most important reason for preference; 10 = least important reason

Article Snippet: Tysabri (natalizumab), developed by Biogen, is a recombinant humanized IgG4 monoclonal antibody for the treatment of adults with highly active RRMS.

Techniques:

Journal: Neurology and Therapy

Article Title: Time and Motion Study to Quantify Time for Tysabri (Natalizumab) Intravenous Versus Subcutaneous to Treat Relapsing-Remitting Multiple Sclerosis in France, Spain, and the United Kingdom

doi: 10.1007/s40120-026-00888-1

Figure Lengend Snippet: Mean importance of reasons for preference of natalizumab SC related to administration. HCP healthcare professional, SC subcutaneous. 1 = most important reason for preference; 10 = least important reason for preference

Article Snippet: Tysabri (natalizumab), developed by Biogen, is a recombinant humanized IgG4 monoclonal antibody for the treatment of adults with highly active RRMS.

Techniques: